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Objective: To study the pharmacological effects of Gel-200, cross-linked hyaluronate.
Experimental design: We examined the chondroprotective, anti-inﬂammatory and analgesic effects of
Gel-200 in experimental animal models for osteoarthritis (OA) and in a human synovial sarcoma cell line
and normal human articular chondrocytes.
Results: In the OA model, a single-dose intra-articular (IA) injection of Gel-200 signiﬁcantly suppressed
cartilage degeneration and reduced synovitis of the knee joint. In the joint pain model, Gel-200 signif-
icantly suppressed pain responses for 4 weeks after injection. The residual property of Gel-200 in the
knee joint tissue was investigated in rabbits. The mean residual ratio of injected Gel-200 in the synovium
was 3.3% (95% conﬁdence interval [CI], 2.4e4.2) at 28 days after the injection. The long-lasting analgesic
effect of Gel-200 might be explained by its high residual ratio in the joint. In addition, we investigated
the mechanism of action of Gel-200 in a human synovial sarcoma cell line and normal human articular
chondrocytes. Gel-200 inhibited IL-1b-induced production of MMP-1, 3 and 13 in human chondrocytes
and production of prostaglandin E2 in human synoviocytes in a concentration-dependent manner,
respectively.
Conclusion: A single-dose IA injection of Gel-200 exerts chondroprotective and anti-inﬂammatory effects
in the experimental OA model, and long-lasting analgesia in the joint pain model, suggesting the
beneﬁcial multimodal function of Gel-200 against symptomatic OA patients.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) of the knee is the most common joint dis-
order throughout the world and is one of the leading causes of
disability in the elderly. Intra-articular (IA) injection of hyaluronic
acid (HA) is a recognized treatment for pain associated with
symptomatic knee OA1e3. HA products are divided into two major
types, native HA products and cross-linked HA products. Native
HA products are injected three to ﬁve times per one treatment
course and its safety has been established based on long time
clinical experiences4. In the cross-linked HA category of the US
market, there are three products, Gel-One, Synvisc and Synvisc-
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ternational. Published by Elsevier LGel-One is the most recently approved single injection prod-
uct in the US market and is composed of Gel-200 which is a novel
cross-linked hyaluronate hydrogel manufactured by photo-
gelation technology. The polysaccharide chains of hyaluronan in
Gel-200 are bound to each other via dimers of cinnamic acid
with ultraviolet irradiation resulting in a clean cross-linked
highly viscoelastic hydrogel. The photocurable hyaluronan de-
rivative chemically linked with cinnamic acid, intermediate of
Gel-200, is puriﬁed before the cross-linking reaction. Gel-200 is
cross-linked by only ultraviolet irradiation without any addi-
tional condensation reagents. This photo-gelation technology
need not required elimination of residual reagents and/or by-
products after cross-linking to achieve high puriﬁcation. In a
multi-center randomized controlled trial in patients with
symptomatic OA of the knee, a single injection of Gel-200 was
well tolerated and relieved pain associated with symptomatic OA
of the knee over 13 weeks5. In this study, we investigated the
pharmacological effects of Gel-200 in animal models (rabbits and
rats), the human synovial sarcoma cell line, and normal human
articular chondrocytes.td. All rights reserved.
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Animals
Animals were quarantined and acclimatized to the environ-
mental conditions for 1 week. The animal studies were reviewed
and approved by the In-house Animal Experiment Ethics Com-
mittee, performed under the animal husbandry/management sys-
tem in an appropriate environment with animal protection/welfare
in mind.
OA model in rabbits
Twenty-four male Japanese White rabbits (16 weeks-old) were
obtained from Oriental Yeast Co., Ltd. The rabbit anterior cruciate
ligament (ACL) transection model was used in this study. The
rabbit ACL transection model is accepted as an arthritis model
which produces cartilage degeneration similar to OA in humans6.
Following induction of anesthesia by a solution containing equal
proportions of ketamine (Veterinary Ketalar50, 50 mg/mL, Sankyo
Yell Yakuhin Co., Ltd., Tokyo, Japan) and xylazine (Selactal 2% in-
jection solution, Bayer Co., Osaka, Japan), rabbits were anes-
thetized by the inhalation of isoﬂurane (Forane, Dainippon
Sumitomo Pharma Co., Ltd., Osaka, Japan). The incision area was
sterilized with 70% ethanol and Isodin solution (Meiji Seika Kaisha
Ltd., Tokyo Japan). An arthrotomy was performed in only the left
knee using a lateral parapatellar approach with 2 cm skin incision.
The ACL was visually transected with a # 15 blade. After the knee
was repositioned, the synovial membrane and skin were sutured
with 4-0 nylon. The animals were allocated to two groups at 4
weeks after ACL transection surgery. Animals without abnormal-
ities were allocated to two groups (n ¼ 12) based on the body
weights and the width of the operated knee joints, using stratiﬁed
continuous randomization. Gel-200 (manufactured by Seikagaku
Corporation) or phosphate buffered saline (PBS) was administered
in a single dose into the joint cavities of the left hindlimbs at a
volume of 50 mL/kg/joint. Necropsy was performed at 9 weeks
after surgery. Blood was drawn from the heart using a heparin-
ized 21G needle under ketamine general anesthesia and animals
were euthanized by exsanguination. Plasma was obtained by
centrifugation at 3,000 rpm for 15 min, and was stored
below 20C.
The left knee was dissected and 2 mL physiological saline was
injected into the joint cavity. The lavage ﬂuid was aspirated and
collected. These procedures were repeated twice on each joint. The
synovium and femur were removed for histopathological assess-
ment and ﬁxed in 10% neutral buffered formalin solution.
Gross morphological assessment of cartilage degeneration was
performed according to the reported procedure7. The severity of the
degeneration was scored based on the criteria shown in Table I (a
total of 12 joints, 24 scores, in each group). The damaged length and
width were measured using a digital caliper.Table I
Cartilage degeneration scoring criteria
Findings Grade
Intact surface (No staining by Indian ink) 1
Minimal ﬁbrillation (Surface retains the ink as elongated specks) 2
Overt ﬁbrillation 3
Erosion (Loss of cartilage exposing the sub-cartilaginous bone) 4
0 mm < Erosion  2 mm in length 4a
2 mm < Erosion  5 mm in length 4b
5 mm < Erosion 4c
5 mm  2 mm < Erosion (mm in length  width) 4dThe volume of the synovial ﬂuid (SFV)8 was determined from
the volume of the recovered SF and the calcium concentrations in
the recovered SF and plasma. The calcium concentration was
measured using a commercial assay kit (Calcium-C test Wako,
Wako Pure Chemical Industries, Ltd., Osaka, Japan): SFV (mL/
joint) ¼ calcium content in SF (mg/joint)/calcium concentration in
plasma (mg/mL).
The total protein content in the SF was measured by a com-
mercial assay kit (BCA Protein Assay Kit, PIERCE, USA). The
prostaglandin E2 (PGE2) content in the SF was measured using a
commercial assay kit (PGE2 EIA kit [Enzo Life Sciences, Inc., PA,
USA]). Parafﬁn sections were prepared from formalin-ﬁxed
synovium and stained with hematoxylin-eosin (HE). Using the
synovium preparations, the severity of the inﬂammation was
evaluated histopathologically from: (1) the cuboidal/stratiﬁed
synovial lining cells, (2) cellular inﬁltration, (3) ﬁbrosis/edema,
and (4) hemorrhage in the synovial tissue. Following EDTA (Life
Technologies Corporation, CA, USA) decalciﬁcation and safranine
O staining, changes in the femur were observed in: (1) areas of
the cartilage matrix with unstained/decreased staining for safra-
nine O, (2) ﬁssure formation in the cartilage matrix, (3) ﬁbrillation
of the cartilage matrix, (4) cartilage defect, (5) increase in the
number of chondrocytes, (6) decrease in the number of chon-
drocytes, (7) remodeling of the sub-cartilaginous bone, and (8)
blood vessel invasion in the cartilage matrix. These severities
were scored on a 4-point scale of Grade 0 (No change) to 3 (Se-
vere change).Bradykinin induced-arthritic pain model in rats
Male SpragueeDawley rats were obtained from Charles River
Laboratories Japan Inc. (Tokyo, Japan). We used the rat joint pain
model, induced by injecting bradykinin (an endogenous hyper-
algesic substance) with PGE2 (a pain enhancer), which has been
used to assess the analgesic effects of hyaluronan preparations
based on the behavioral manifestations of joint pain in gait such as
“lifting the foot”, “claudication” and “walking on three legs”9,10 or
pain-related behaviour using a dynamometer and weight
bearing11. Rats were given general anesthesia by an isoﬂurane
small animal anesthetizer. Gel-200 or PBS was administered in a
single dose with a 29G needle-tipped syringe into the joint cavity
at a volume of 50 mL/joint (n ¼ 12, each evaluation point), which
dose is generally used for injection into the articular cavity of
rats9,10. Bradykinin (Peptide Institute, Inc., Osaka, Japan) was dis-
solved and diluted with PBS at a concentration of 16 mg/mL. PGE2
(Cayman Chemical Company, MI, USA) for enhancing bradykinin-
induced pain was dissolved in ethanol and the solution was
diluted with PBS at a concentration of 4 mg/mL. The bradykinin
solutions were prepared from equal volumes of bradykinin and
PGE2 solutions. A Fast Green FCF was added to bradykinin solu-
tions to detect leakage from the joint cavity. The colored solutions
were sterilized by ﬁltration using a 0.22-mm ﬁlter and used for
injection.
The bradykinin solutions were injected at 1, 2 and 4 weeks after
Gel-200 or PBS administration to induce pain. To assess the pain
response accurately, no anesthesia was used. The bradykinin so-
lution was injected into the rats that received the test materials.
Under blinded conditions, each animal was observed walking for
2 min after the bradykinin solution injection. The severity of pain
was scored using criteria by Gotoh et al.9 (Table II). After the anal-
gesic assessments, all the rats were sacriﬁced by exsanguination
under general anesthesia without pain. The knee joint was exposed
through an incision and the injection site was conﬁrmed by the
green-colored bradykinin solution in the joint cavity.
Table II
Criteria for assigning pain scores
Behavioral manifestation Score
Normal or claudication for  5 s 0
Claudication for 6e30 s 1
Showing one of the following two manifestations: 2
Claudication for  31 s
Lifting the foot for  5 s
Showing one of the following two manifestations: 3
Lifting foot followed by claudication
Walking on three legs for  5 s
Walking on three legs for  6 s 4
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knee in rabbits
Thirty female Japanese White rabbits (15e18 weeks-old) were
obtained from Oriental Yeast Co., Ltd. Anesthesia was induced by a
solution containing equal proportions of ketamine, xylazine, and
physiological saline. Gel-200 was injected in a single dose into the
joint cavities of both hindlimbs under anesthesia (n ¼ 5, 10 knee
joints per group) at a volume of 50 mL/kg/joint. Necropsy was
performed at 1, 3, 5, 7, 14 and 28 days after the injection of Gel-200.
Animals were sacriﬁced by exsanguination under ketamine general
anesthesia. After the knee was dissected, the synovial ﬂuid (SF) was
collected by washing the joint cavity 2 times with 2 mL physio-
logical saline. The synoviumwas removed and digested at 55C for
40 h with 5 mL of 2 mg/mL proteinase K (SigmaeAldrich Co., MO,
USA) solution (43 units/mg protein). The residual ratio of Gel-200
in the SF and the synovium was calculated using the amount of
injected Gel-200 and the quantiﬁed trans-cinnamic acid contents, a
component of Gel-200, in preparations recovered from the test
animals. Preparation of the samples of the SF and the synovium
digest, as well as the experimental conditions for analysis were
performed in a preliminary study; the trans-cinnamic acid was
extracted under alkaline conditions from the SF and the synovium
digest, and then quantiﬁed by high-performance liquid chroma-
tography (HPLC) with an octadecylsilyl (ODS) column.Measurement of matrix metalloproteinase-1, -3, and -13 production
by human chondrocytes
Normal human articular chondrocytes (NHAC-Kn, Lonza Wal-
kersville, Inc., MD, USA), were seeded in 24-well plates at a density
of 2  105 cells/well in DMEM/F-12 (Life Technologies Corporation,
CA, USA) medium containing 10% heat-inactivated FBS (Sigmae
Aldrich Co., MO, USA) and incubated at 37C under 5% CO2. After
24 h, the cells were preincubated with or without Gel-200 in the
concentration range of 0.1e3.0 mg/mL for 30 min. The cells were
stimulated with 10 mL of rhIL-1b (ﬁnal concentration, 10 ng/mL) to
induce MMP-1, -3 and -13 production in the presence or absence of
Gel-200. After 16 h, the MMPs contents in the conditioned media
were determined with Quantiline enzyme-linked immunosorbent
assay (ELISA) kits (R&D Systems, MN, USA).Measurement of prostaglandin E2 production by human
synoviocytes
Human synovial sarcoma cells (SW982, American Type Culture
Collection, VA, USA), were seeded in 48-well plates at a density of
3104 cells/0.5mL/well in RPMI 1640medium containing 10% heat-
inactivated FBS and 1% penicillin/streptomycin, incubated at 37C
under 5%CO2. After 48 h, the culture supernatantswere removed and
the solution of the test materials with IL-1bwas then added to eachwell. The concentration of Gel-200was 0.003e3.0mg/mL, and it was
incubated for 42 h. PGE2 levels were measured after stimulation of
the cells with rhIL-1b (ﬁnal concentration,10 ng/mL) at 37C for 42 h.
After incubation, samples of the medium were collected for deter-
mination of PGE2 with PGE2 ELISA kits (Assay Designs Inc., MI, USA).
Three independent experiments were performed. For another set,
SW982was placed in a 48-well plate and incubated for 44 h. The cells
were incubated with or without anti-CD44 antibody IM7 (BD Bio-
sciences, CA, USA) at 50 mg/mL for 4 h. After 4 h, the supernatants
were removed and Gel-200 (ﬁnal concentration, 3 mg/mL) and IL-1b
(ﬁnal concentration, 10 ng/mL) were added to each well. They were
incubated for 42 h as previously described.
Statistical analyses
Statistical analyses were performed using SAS (SAS Institute Inc.,
NC, USA). Direct effects from treatment with Gel-200were assessed
using aWilcoxon rank sum test for grossmorphological assessment
of cartilage degeneration and analgesic assessment of the joint pain
model in rats. Student’s t-test was performed for assessment of the
volume of SF, protein content and PGE2 content in the SF. Williams’
test was performed for assessment of PGE2, MMP-1, -3, and -13
production in vitro. Results of the measurements in each group
were represented as the mean and 95% conﬁdence intervals (CI).
Any P-values of <0.05 were considered statistically signiﬁcant.
Results
We investigated the chondroprotective and anti-inﬂammatory
effects of Gel-200 in the rabbit OA model, the analgesic effects in
a rat joint pain model, the inhibitory effects of prostaglandin E2 and
MMPs production in a human synovial sarcoma cell line, and
normal human articular chondrocytes to reveal the mechanism of
action of Gel-200.
Gross morphological assessment of cartilage degeneration in the
rabbit OA model
In the macroscopic picture, the damaged areas of the femoral
condyle, which were stained by India ink were more severe in the
control group [Fig. 1(A)]. The percentage of animals with mild
degeneration (Grade 1e3) was higher in the Gel-200 group
[Fig. 1(B)]. The percentage of animals with Grade 4 (exposure of
sub-cartilaginous bone) was 67% (16/24 of total points) in the
control group vs 16% (4/24 of total points) in the Gel-200 group.
Progression of the cartilage degeneration was signiﬁcantly sup-
pressed in the Gel-200 group compared to the control group
(P < 0.0001, Wilcoxon rank sum test).
Histopathological examination of the articular cartilage in the rabbit
OA model
Histopathological changes were observed in: the areas of the
cartilagematrix unstained/decreased staining for safranin O, ﬁssure
formation in the cartilagematrix, ﬁbrillation of the cartilagematrix,
the cartilage defect, increase in the number of chondrocytes,
decrease in the number of chondrocytes, remodeling of sub-
cartilaginous bone and blood vessel invasion in the cartilage ma-
trix. A lesion with ﬁbrillation exhibited decreased staining for
safranin O and a decrease in chondrocytes. Decrease in the number
of chondrocytes was observed as cluster formations and found
around degenerative lesions. Bone remodeling in the sub-
cartilaginous bone and blood vessel invasion in the cartilage ma-
trix were observed beneath a severe degenerative lesion in the
cartilage. These changes were less severe in the Gel-200 group
Fig. 1. (A) These representative macroscopic pictures of articular cartilage of the femoral condyles were taken at 9 weeks after ACL transection surgery. In the control group, the
surface of the femoral condyle had severe cartilage erosion which stained with India ink. However, in the Gel-200 group, the erosion area was seen to be less than in the control
group. (B) Morphological assessment of cartilage damage. As the severity of cartilage lesions increases, so does the score obtained using the previous report. The control group was
administered PBS after surgery. Gel-200 groups were administered Gel-200 once. P-values were determined by the Wilcoxon rank sum test (n ¼ 12 [24 points] per group). (C) These
representative photomicrographs were taken at 9 weeks after ACL transection, the stain used is Safranin O and Fast green, and the magniﬁcation is 40. The Safranin O stain
displays GAGs content within the cartilage (GAGs: red, Bone and collagen ﬁbers: green). In the Gel-200 group, the severity of the cartilage degeneration was less severe compared
with that of the control group.
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scores for the articular cartilage were 13.0 (n ¼ 12; 95% CI, 11.7e
14.3) in the control group and 9.8 (n ¼ 12; 95% CI, 7.9e11.7) in the
Gel-200 group, respectively. Themean histological score of the Gel-
200 group was statistically signiﬁcantly lower than the control
group (Student t-test, P ¼ 0.01).
Volume of the synovial ﬂuid (SFV), total protein and PGE2 content in
the SF
The mean SFV was 0.901 mL/joint (n ¼ 12; 95% CI, 0.779e
1.023) in the control group, and 0.558 mL (n ¼ 12; 95% CI, 0.442e0.674) in the Gel-200 group, which showed signiﬁcant suppres-
sion of the SFV compared to that in the control group [Fig. 2(A),
Student t-test, P < 0.001]. The mean protein content in the SF was
15.4 mg/joint (95% CI, 12.3e18.5) in the control group, whereas it
was 9.3 mg/joint (95% CI, 6.7e11.9) in the Gel-200 group
[Fig. 2(B)]. The decreases in the protein contents in the Gel-200
group were statistically signiﬁcant compared to that in the con-
trol group (Student t-test, P ¼ 0.007). The mean PGE2 content in
SF was 519 pg/joint (95% CI, 381e657) in the control group
[Fig. 2(C)], whereas that in Gel-200 group was 278 pg/joint (95%
CI, 148e408). Gel-200 signiﬁcantly decreased PGE2 content in SF
(Student t-test, P ¼ 0.021).
Fig. 2. (A) The volume of SF in the joint cavities at 9 weeks after ACL transection. Four weeks after ACL transection, the test materials were administered into the joint cavities at a
volume of 50 mL/kg/joint. Nine weeks after ACL transection, synovial ﬂuid (SF) was collected by washing the joint cavity 2 times with 2 mL physiological saline. Gel-200 signiﬁcantly
suppressed the increase in volume of the SF. (B) The total protein content in synovial ﬂuid. The total protein content in synovial ﬂuid was measured using a commercial assay kit
(BCA Protein Assay Kit, PIERCE, USA). Values represent the means  95% CI. P-values were determined by the Student’s t-test (n ¼ 12 per group). (C) The PGE2 content in synovial
ﬂuid. The PGE2 content in synovial ﬂuid was measured using a commercial assay kit (PGE2 EIA Kit, Enzo Life Sciences, Inc., USA). Values represent the means  95% CI. P-values were
determined by the Student’s t-test (n ¼ 12 per group). (D) These representative photomicrographs were taken at 9 weeks after ACL transection. Parafﬁn sections were made from
formalin-ﬁxed synovium and stained with HE. The magniﬁcation is 10 or 40. The following histopathological observations were carried out and scored for synovium: cuboidal/
stratiﬁed synovial lining cells, cellular inﬁltration, ﬁbrosis/edema, hemorrhage and calcium deposition in synovial tissue. The severity of the changes was slighter in the Gel-200
group.
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The histopathological changes were observed and scored
based on a 4-point scale of Grade 0 (No change) to 3 (Severe
change) in the synovium of: cuboidal synovial lining cells,
stratiﬁed synovial lining cells, cellular inﬁltration, ﬁbrosis/
edema, and hemorrhage in the synovial tissue. The severity of
the changes was slightly less in the Gel-200 group [Fig. 2(D)]. The
mean total histological score for the synovium in the control
group was 8.8 (n ¼ 12; 95% CI, 8.0e9.6), whereas it was 7.4
(n ¼ 12; 95% CI, 5.9e8.9) in the Gel-200 group. A trend of lower
scores was seen in the Gel-200 treated group, though this dif-
ference was not statistically signiﬁcant.Bradykinin induced-arthritic pain model in rats
The pain scores using the 5-point scale are shown in Fig. 3. Gel-
200 reduced bradykinin-induced arthritic pain with statistically
signiﬁcant differences as compared to the control group at 1, 2, and
4 weeks after the injection (n ¼ 12 each evaluation point, Wilcoxon
rank sum test, P < 0.001, P ¼ 0.003, and P ¼ 0.016, respectively).
Residual ratio of Gel-200 in the joint cavity (SF) and synovium of the
knee in rabbits
The residual property of Gel-200 in the SF and the synovium
was investigated (n ¼ 5, 10 knee joints each evaluation point).
Fig. 3. Gel-200 or PBS was injected in a single dose into the joint cavities of the left
hindlimb at a volume of 50 mL/joint. One, 2, or 4 weeks after the injection, walking of
each animal was observed for 2 min after injection of the bradykinin solutions under
blinded conditions. The severity of pain was scored according to the 4-point scale.
Values represent the means  95% CI. P-values of 1-, 2- and 4-week group were
determined by the Wilcoxon’s t-test (n ¼ 12 per group).
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immediately between 1 and 28 days, as shown in Fig. 4. The re-
sidual ratio decreased up to 7 days after Gel-200 injection and
subsequently Gel-200 was not detected in the SF. In the synovium,
the administered Gel-200 was detected between 1 and 28 days
after the injection. The mean residual ratio of injected Gel-200 in
the synovium was 3.3% (95% CI, 2.4e4.2) at 28 days after the
injection.Measurement of matrix metalloproteinase-1, -3, and -13 production
by human chondrocytes
The production of MMP-1, MMP-3 and MMP-13 is stimulated by
IL-1b in human chondrocytes. When human chondrocytes were
incubated with IL-1b in the presence of Gel-200, Gel-200 signiﬁ-
cantly inhibited the production of MMP-13 and MMP-3 in human
chondrocytes at concentrations from 0.1 to 3 mg/mL in a
concentration-dependent manner [Fig. 5(A) and (B)]. Gel-200Fig. 4. Gel-200 was administered into the joint cavities of both hindlimbs at a volume
of 50 mL/kg/joint in rabbit. Necropsy was performed on days 1, 3, 5, 7, 14 and 28 after
injection of the test material. The residual ratio of Gel-200 in the synovial ﬂuid and the
synovium was calculated by quantifying trans-cinnamic acid, a component of Gel-200,
in preparations recovered from the test rabbits. Values represent the means  95% CI
(n ¼ 5, 10 knee joints per group) (B) synovial ﬂuid; (C) synovium.showed a trend toward inhibition in MMP-1 production. Only at
the maximum concentration (3 mg/mL), its inhibitory effect was
signiﬁcant [Fig. 5(C)].Measurement of PGE2 production by human synoviocytes
The production of PGE2 is stimulated by IL-1b in human syno-
viocytes. When human synoviocytes were incubated with IL-1b in
the presence of Gel-200, the levels of secreted PGE2 were decreased
in a concentration-dependent manner [Fig. 6(A)]. Gel-200 sup-
pressed PGE2 production in the range of 0.03e3 mg/mL in a
concentration-dependent manner. The percent inhibition of 0.03,
0.3 and 3 mg/mL Gel-200 was 18.4, 44.9% and 49.2%, respectively.
When human synoviocytes were incubated for 44 h after 4 h of
preincubation with 50 mg/mL of anti-CD44 antibody IM7, the
inhibitory effect of 3 mg/mL of Gel-200 was partially reversed
[Fig. 6(B)].Fig. 5. Human chondrocytes were incubated with 10 ng/mL IL-1b in the absence or
presence of Gel-200 at various concentrations (0.1, 0.3, 1, 3 mg/mL) for 16 h. Secreted
MMP-1, MMP-3 and MMP-13 were measured by ELISA. Values represent means  95%
CI in six wells. Data shown are representative of three independent experiments.
***P < 0.0001, signiﬁcant difference from the control group by the Williams test.
Fig. 6. Human synoviocytes were incubated with 10 ng/mL IL-1b in the absence or
presence of Gel-200 at various concentration (0.003, 0.03, 0.3, 3 mg/mL) for 42 h.
Secreted PGE2 in the supernatants was measured by ELISA. Values represent
means  95% CI in six wells. Data shown are representative of three independent
experiments. ***P < 0.0001, signiﬁcant difference from the control group by the Wil-
liams test.
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The effect of Gel-200 was comprehensively evaluated by
comparing the morphological assessment of the parameters of
cartilage degeneration, indicators of hydrarthrosis including the
SFV, total protein content, PGE2 content and histopathological ex-
amination using a rabbit OA model. These results demonstrate that
single-dose IA injection of Gel-200 prevented cartilage degenera-
tion more effectively than PBS. The OA model used in the present
study is produced by transecting the ACL, resulting in irreversible
degeneration of the cartilage over an extended period of time. The
cartilage changes are similar to those observed in human OA12.
Therefore, the ACL transection model has been frequently used as
an arthritis model for the evaluation of hyaluronan preparations13e
15 or glucosamine16. In the previous studies, it was reported that
three IA injections of hylan G-F 2015 and HYADD 4-G17 or ﬁve IA-HA
injections13,14 had chondroprotective effects in this model. It is
considered that HA acts as a shock absorber or mechanical stabi-
lizer for the nociceptors in the joints18. Belmonte C et al. report that
IA-HA reduces pain through its effect on peripheral pain receptors,
increasing the viscoelastic properties of the SF19. Furthermore, as
the possible mechanism, HA itself may trap NO molecules, and
protect against chondrocyte apoptosis during the development of
OA20. Since NO production in the meniscus and synovium of the HAtreated group were signiﬁcantly lower than that in the control, the
inhibition of NO production might be part of the mechanism of the
therapeutic effect of HA on OA21. Hashimoto et al. report that there
are signiﬁcant correlations between NO release and chondrocyte
apoptosis and between OA severity and chondrocyte apoptosis22.
Additionally, since HA inhibits MMP-3 and IL-1b production in the
synovium in the ACL transection model, one mechanism of HA
might be down-regulation of MMP-3 and IL-1b production in the
synovium during the early development of OA23.
This study is the ﬁrst report of the chondroprotective effects of
HA with a single-dose IA injection. This effect appeared to result
from the high viscosity and elasticity of Gel-200, which produces
sustained lubrication and protective action against abrasion and
physical stress from its sustained presence in the joint cavity for a
longer period of time than unmodiﬁed hyaluronan. In addition, Gel-
200 inhibited IL-1b-induced MMP production in human chon-
drocytes in a concentration-dependent manner. MMP is expressed
by chondrocytes and synovial cells in human OA and is thought to
play a critical role in cartilage destruction24e27. Mehraban F et al.
demonstrated that MMP-3 is initially upregulated in the synovium
which may play a pivotal role in the pathogenesis of cartilage,
however, chondrocyte-derived MMP-3 is upregulated in the later
phase, contributing further to progression of the cartilage lesions28.
We speculate that the chondroprotective effect of Gel-200 is due to
the inhibition of MMP production. The minimal effective concen-
tration of Gel-200 for MMP-1 (3 mg/mL) was higher than for MMP-
3, 13 (100 mg/mL). It has been reported that HA inhibits phos-
phorylation by p38mitogen-activated protein kinase (MAPK) via its
principal receptor, CD44, and exerts an anti-inﬂammatory ef-
fect29,30. Gel-200 weakly inhibited MMP-1 compared with the
other MMPs, because p38 MAPK contributed slightly to the pro-
duction of MMP-1. Okada A et al. describes that MMPs are involved
in cartilage degeneration via the fragmentation of aggrecan and
collagen, and are increased in the SF of OA patients25. In the present
study, the inhibitory effects of MMP production by Gel-200 were
considered to contribute to the articular cartilage protection in
knee OA.
Gel-200 appeared to improve synovitis, as judged from the
reduction in the increase in SFV, total protein and PGE2 content in
SF. Since cartilage degeneration is milder when synovitis is not
severe, these changes induced by Gel-200 may interact beneﬁcially
to reduce the progression of the pathological changes. The histo-
pathological observations also support this conclusion. In fact,
glycosaminoglycan (GAG) in the cartilage matrix and surviving
chondrocytes was maintained to a greater degree in the Gel-200
group and the cartilage degeneration was mild. On the other
hand, Gel-200 improved the cuboidal/stratiﬁed synovial lining
cells, cellular inﬁltration, ﬁbrosis/edema and hemorrhage in the
synovial tissue and suppressed the inﬂow of blood components
into the joint cavity by alleviating the synovitis. These results
suggest that Gel-200 may suppress the synovitis associated with
knee OA.
In the second study, Gel-200 exerted a long-lasting analgesic
effect for up to 4 weeks in rats. The mechanism by which Gel-200
acts in the pain model is unclear. However, the analgesic effect
assessed by this pain model was reported to be associated with the
concentration of hyaluronan in synovial tissue9,10. We examined
the local retention of Gel-200 in the synovium and SF after a single-
dose IA injection in rabbits. Gel-200 was retained in the synovium
at least at 28 days [Fig. 4]. We speculate that Gel-200 administered
into the joint cavity penetrated to the synovium, and was retained
there for a long time. Although the remaining amount of Gel-200
may be small, it was thought that sufﬁcient Gel-200 for the phar-
macological effect to be shown remained in the synovium at 28
days after injection. Furthermore, Gel-200 decreased PGE2
K. Yoshioka et al. / Osteoarthritis and Cartilage 22 (2014) 879e887886production in a concentration-dependent manner in human syn-
oviocytes. The inhibitory effect of Gel-200 was partially reversed by
pretreatment with anti-CD44 antibody IM7. We considered the
mechanism of Gel-200 action was biologically mediated by CD44,
but not the rheological properties. It has been reported that HA
inhibits PGE2 production, and that pretreatment with OS/37, a
monoclonal antibody speciﬁc for the hyaluronate-binding epitope
on CD44, reverses the inhibitory effects of HA31. The inhibition of
PGE2 production by HA was also conﬁrmed in a clinical study32.
These ﬁndings suggest that Gel-200 exerts an analgesic effect via
multimodal functions, and the effects of Gel-200 are similar to
those observed with other HA preparations. We consider that the
long-lasting pharmacological effect is associated with the sustained
local retention in the synovium and SF. Moreover, in order to
calculate the half-life of Gel-200, additional examination with a
radioisotope is required.
In conclusion, results in our non-clinical studies showed that the
single-dose IA injection of Gel-200 exerted chondroprotective,
anti-inﬂammatory effects, and long-lasting analgesia, suggesting
the beneﬁcial multimodal function of Gel-One in patients with
symptomatic OA.
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